Diabetes Care, Vol 22, Issue 1 125-132, Copyright © 1999 by American Diabetes Association

ARTICLES

Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease

YM Smulders, M Rakic, EH Slaats, M Treskes, EJ Sijbrands, DA Odekerken, CD Stehouwer and J Silberbusch
Department of Internal Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.

OBJECTIVE: The increased cardiovascular risk in subjects with NIDDM is partly explained by an association with established risk factors like hypertension, dyslipidemia, and obesity. Mild hyperhomocysteinemia has emerged as a new risk factor for cardiovascular disease. The purpose of this study was to assess its role in NIDDM. RESEARCH DESIGN AND METHODS: We studied predictors of homocysteine levels and correlations between homocysteine and (micro-)albuminuria, retinopathy, and history of cardiovascular disease in normotensive NIDDM subjects under stable metabolic control. This was done in 85 NIDDM subjects by measuring fasting and post-methionine-loading homocysteine levels together with blood pressure, BMI, serum cholesterol, triglyceride, HDL cholesterol, folate, vitamin B12, pyridoxal-5-phosphate, HbA1c, and (micro-)albuminuria and creatinine clearance in triplicate 24-h urine samples. The relationship between micro- and macrovascular complications and fasting homocysteine only was studied in an additional 65 subjects, giving a total of 150 subjects. RESULTS: In multiple regression analysis, significant (P < 0.05) predictors of fasting homocysteine were low-normal values of creatinine clearance (threshold effect at < 80 ml.min-1 .1.73 m-2), folate (< 20 nmol/l), and vitamin B12 (< 350 pmol/l), and postmenopausal status in women. Determinants of post-methionine homocysteine were pyridoxal-5-phosphate levels < 80 nmol/l, creatinine clearance, and sex (higher levels in women). Hyperhomocysteinemia did not cluster with other cardiovascular risk factors, like hypertension, obesity, or dyslipidemia. Regarding cardiovascular complications, fasting homocysteine, but not post-methionine homocysteine, was higher in subjects with a history of cardiovascular disease. There was a stepwise increase in the prevalence of subjects with cardiovascular disease with increasing fasting homocysteine. The prevalence of cardiovascular disease was 19.4% in the bottom quartile of fasting homocysteine, versus 55.0% in the top quartile (P for trend < 0.01). Neither fasting homocysteine nor post-methionine homocysteine correlated with (micro-)albuminuria or with retinopathy. CONCLUSIONS: The findings suggest that homocysteine levels in NIDDM rise even with modest deterioration of renal function and when vitamin status is in the low to low-normal range. Fasting homocysteine correlates with macrovascular disease, but we found no evidence of a correlation with retinopathy or (micro-)albuminuria. Post-methionine homocysteine levels do not show a correlation with micro- or macrovascular complications.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. Brazionis, K. Rowley Sr., C. Itsiopoulos, C. A. Harper, and K. O'Dea Homocysteine and Diabetic Retinopathy Diabetes Care, January 1, 2008; 31(1): 50 - 56. [Abstract] [Full Text] [PDF]

				F. Q. Nuttall, K. Schweim, H. Hoover, and M. C. Gannon Metabolic effect of a LoBAG30 diet in men with type 2 diabetes Am J Physiol Endocrinol Metab, October 1, 2006; 291(4): E786 - E791. [Abstract] [Full Text] [PDF]

				M. R. Skilton, N. T. Lai, K. A. Griffiths, L. M. Molyneaux, D. K. Yue, D. R. Sullivan, and D. S. Celermajer Meal-related increases in vascular reactivity are impaired in older and diabetic adults: insights into roles of aging and insulin in vascular flow Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1404 - H1410. [Abstract] [Full Text] [PDF]

				L. Sparre Hermann, B. Nilsson, and S. Wettre Vitamin B12 status of patients treated with metformin: a cross-sectional cohort study The British Journal of Diabetes & Vascular Disease, November 1, 2004; 4(6): 401 - 406. [Abstract] [PDF]

				M. Soinio, J. Marniemi, M. Laakso, S. Lehto, and T. Ronnemaa Elevated Plasma Homocysteine Level Is an Independent Predictor of Coronary Heart Disease Events in Patients with Type 2 Diabetes Mellitus Ann Intern Med, January 20, 2004; 140(2): 94 - 100. [Abstract] [Full Text] [PDF]

				Y. Aso, K.-i. Okumura, K. Takebayashi, S. Wakabayashi, and T. Inukai Relationships of Plasma Interleukin-18 Concentrations to Hyperhomocysteinemia and Carotid Intimal-Media Wall Thickness in Patients With Type 2 Diabetes Diabetes Care, September 1, 2003; 26(9): 2622 - 2627. [Abstract] [Full Text] [PDF]

				A. N. Friedman, L. G. Hunsicker, J. Selhub, A. G. Bostom, and The Collaborative Study Group Proteinuria as a Predictor of Total Plasma Homocysteine Levels in Type 2 Diabetic Nephropathy Diabetes Care, November 1, 2002; 25(11): 2037 - 2041. [Abstract] [Full Text] [PDF]

				B. Ozmen, D. Ozmen, N. Turgan, S. Habif, I. Mutaf, and O. Bayindir Association Between Homocysteinemia and Renal Function in Patients with Type 2 Diabetes Mellitus Ann. Clin. Lab. Sci., July 1, 2002; 32(3): 279 - 286. [Abstract] [Full Text] [PDF]

				M.-C. Beauchamp and G. Renier Homocysteine Induces Protein Kinase C Activation and Stimulates c-Fos and Lipoprotein Lipase Expression in Macrophages Diabetes, April 1, 2002; 51(4): 1180 - 1187. [Abstract] [Full Text] [PDF]

				J.-M. Gonzalez-Clemente, R. Deulofeu, J. Mitjavila, G. Galdon, E. Ortega, A. Caixas, G. Gimenez-Perez, and D. Mauricio Plasma Homocysteine Is not Increased in Microalbuminuric Patients With Type 2 Diabetes Without Clinical Cardiovascular Disease Diabetes Care, March 1, 2002; 25(3): 632 - 633. [Full Text] [PDF]

				L. Davies, E. G. Wilmshurst, A. McElduff, J. Gunton, P. Clifton-Bligh, and G. R. Fulcher The Relationship Among Homocysteine, Creatinine Clearance, and Albuminuria in Patients With Type 2 Diabetes Diabetes Care, October 1, 2001; 24(10): 1805 - 1809. [Abstract] [Full Text] [PDF]

				J. B. Meigs, P. F. Jacques, J. Selhub, D. E. Singer, D. M. Nathan, N. Rifai, R. B. D'Agostino Sr., and P. W.F. Wilson Fasting Plasma Homocysteine Levels in the Insulin Resistance Syndrome: The Framingham Offspring Study Diabetes Care, August 1, 2001; 24(8): 1403 - 1410. [Abstract] [Full Text] [PDF]

				C. Pavía, I. Ferrer, C. Valls, R. Artuch, C. Colomé, and M. A. Vilaseca Plasma Homocysteine Levels in Type 1 Diabetic Patients Diabetes Care, May 1, 2001; 24(5): 970 - 971. [Full Text]

				M. Emoto, H. Kanda, T. Shoji, T. Kawagishi, M. Komatsu, K. Mori, H. Tahara, E. Ishimura, M. Inaba, Y. Okuno, et al. Impact of Insulin Resistance and Nephropathy on Homocysteine in Type 2 Diabetes Diabetes Care, March 1, 2001; 24(3): 533 - 538. [Abstract] [Full Text]

				A. Jager, P. J. Kostense, G. Nijpels, J. M. Dekker, R. J. Heine, L. M. Bouter, A. J. M. Donker, and C. D. A. Stehouwer Serum Homocysteine Levels Are Associated With the Development of (Micro)albuminuria : The Hoorn Study Arterioscler. Thromb. Vasc. Biol., January 1, 2001; 21(1): 74 - 81. [Abstract] [Full Text] [PDF]

				E. K. Hoogeveen, P. J. Kostense, P. E. D. Eysink, B. C. P. Polak, P. J. Beks, C. Jakobs, J. M. Dekker, G. Nijpels, R. J. Heine, L. M. Bouter, et al. Hyperhomocysteinemia Is Associated With the Presence of Retinopathy in Type 2 Diabetes Mellitus: The Hoorn Study Arch Intern Med, October 23, 2000; 160(19): 2984 - 2990. [Abstract] [Full Text] [PDF]

				V. Shpichinetsky, I. Raz, Y. Friedlander, N. Goldschmidt, I. D. Wexler, A. Ben-Yehuda, and G. Friedman The Association between Two Common Mutations C677T and A1298C in Human Methylenetetrahydrofolate Reductase Gene and the Risk for Diabetic Nephropathy in Type II Diabetic Patients J. Nutr., October 1, 2000; 130(10): 2493 - 2497. [Abstract] [Full Text]